These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 24015249)
1. Autophagy plays a critical role in ChLym-1-induced cytotoxicity of non-hodgkin's lymphoma cells. Fan J; Zeng X; Li Y; Wang S; Wang Z; Sun Y; Gao H; Zhang G; Feng M; Ju D PLoS One; 2013; 8(8):e72478. PubMed ID: 24015249 [TBL] [Abstract][Full Text] [Related]
2. Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells. Liu C; DeNardo G; Tobin E; DeNardo S Cancer Biother Radiopharm; 2004 Oct; 19(5):545-61. PubMed ID: 15650447 [TBL] [Abstract][Full Text] [Related]
3. A novel therapeutic approach against B-cell non-Hodgkin's lymphoma through co-inhibition of Hedgehog signaling pathway and autophagy. Fan J; Zeng X; Li Y; Wang S; Yang P; Cao Z; Wang Z; Song P; Mei X; Ju D Tumour Biol; 2016 Jun; 37(6):7305-14. PubMed ID: 26666826 [TBL] [Abstract][Full Text] [Related]
4. A chimeric Lym-1/interleukin 2 fusion protein for increasing tumor vascular permeability and enhancing antibody uptake. Hu P; Hornick JL; Glasky MS; Yun A; Milkie MN; Khawli LA; Anderson PM; Epstein AL Cancer Res; 1996 Nov; 56(21):4998-5004. PubMed ID: 8895756 [TBL] [Abstract][Full Text] [Related]
5. What signals are generated by anti-CD20 antibody therapy? Bonavida B Curr Hematol Malig Rep; 2006 Dec; 1(4):205-13. PubMed ID: 20425315 [TBL] [Abstract][Full Text] [Related]
6. Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and Its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma. Stein R; Qu Z; Chen S; Rosario A; Shi V; Hayes M; Horak ID; Hansen HJ; Goldenberg DM Clin Cancer Res; 2004 Apr; 10(8):2868-78. PubMed ID: 15102696 [TBL] [Abstract][Full Text] [Related]
7. Combination immunotherapy with anti-CD20 and anti-HLA-DR monoclonal antibodies induces synergistic anti-lymphoma effects in human lymphoma cell lines. Tobin E; Denardo G; Zhang N; Epstein AL; Liu C; Denardo S Leuk Lymphoma; 2007 May; 48(5):944-56. PubMed ID: 17487739 [TBL] [Abstract][Full Text] [Related]
8. Recombinant human arginase induced caspase-dependent apoptosis and autophagy in non-Hodgkin's lymphoma cells. Zeng X; Li Y; Fan J; Zhao H; Xian Z; Sun Y; Wang Z; Wang S; Zhang G; Ju D Cell Death Dis; 2013 Oct; 4(10):e840. PubMed ID: 24113174 [TBL] [Abstract][Full Text] [Related]
9. Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway. Niu NK; Wang ZL; Pan ST; Ding HQ; Au GH; He ZX; Zhou ZW; Xiao G; Yang YX; Zhang X; Yang T; Chen XW; Qiu JX; Zhou SF Drug Des Devel Ther; 2015; 9():1555-84. PubMed ID: 25792811 [TBL] [Abstract][Full Text] [Related]
10. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention. Jazirehi AR; Bonavida B Oncogene; 2005 Mar; 24(13):2121-43. PubMed ID: 15789036 [TBL] [Abstract][Full Text] [Related]
11. The FACT-targeted drug CBL0137 enhances the effects of rituximab to inhibit B-cell non-Hodgkin's lymphoma tumor growth by promoting apoptosis and autophagy. Lv Y; Du Y; Li K; Ma X; Wang J; Du T; Ma Y; Teng Y; Tang W; Ma R; Wu J; Wu J; Feng J Cell Commun Signal; 2023 Jan; 21(1):16. PubMed ID: 36691066 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of PI3K/Akt/mTOR pathway by ammonium chloride induced apoptosis and autophagy in MAC-T cell. Feng L; Liao H; Liu J; Xu C; Zhong K; Zhu H; Guo S; Guo Y; Han L; Li H; Wang Y Res Vet Sci; 2021 May; 136():622-630. PubMed ID: 33930632 [TBL] [Abstract][Full Text] [Related]
13. Caffeine induces apoptosis by enhancement of autophagy via PI3K/Akt/mTOR/p70S6K inhibition. Saiki S; Sasazawa Y; Imamichi Y; Kawajiri S; Fujimaki T; Tanida I; Kobayashi H; Sato F; Sato S; Ishikawa K; Imoto M; Hattori N Autophagy; 2011 Feb; 7(2):176-87. PubMed ID: 21081844 [TBL] [Abstract][Full Text] [Related]
14. Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis. Stolz C; Hess G; Hähnel PS; Grabellus F; Hoffarth S; Schmid KW; Schuler M Blood; 2008 Oct; 112(8):3312-21. PubMed ID: 18689543 [TBL] [Abstract][Full Text] [Related]
15. A human-mouse chimeric Lym-1 monoclonal antibody with specificity for human lymphomas expressed in a baculovirus system. Hu P; Glasky MS; Yun A; Alauddin MM; Hornick JL; Khawli LA; Epstein AL Hum Antibodies Hybridomas; 1995; 6(2):57-67. PubMed ID: 7492752 [TBL] [Abstract][Full Text] [Related]
16. The prosurvival role of autophagy in resveratrol-induced cytotoxicity in GH3 cells. Zhang X; Xu W; Su J; Chu M; Jin H; Li G; Tan C; Wang X; Wang C Int J Mol Med; 2014 Apr; 33(4):987-93. PubMed ID: 24534837 [TBL] [Abstract][Full Text] [Related]
17. Rituximab enhances radiation-triggered apoptosis in non-Hodgkin's lymphoma cells via caspase-dependent and - independent mechanisms. Skvortsova I; Skvortsov S; Popper BA; Haidenberger A; Saurer M; Gunkel AR; Zwierzina H; Lukas P J Radiat Res; 2006 Jun; 47(2):183-96. PubMed ID: 16819145 [TBL] [Abstract][Full Text] [Related]
18. [Expression of CD16zeta in NK cells of B-cell non-Hodgkin's lymphoma patients and in vitro killing effect of rituximab combined lymphokine-activated killer cells on B-NHL cells]. Shi YX; Zhang XS; Xia JC; Li YQ; Xu RH; Han WJ; Zhang JH; Guan ZZ; Jiang WQ Ai Zheng; 2007 Aug; 26(8):837-42. PubMed ID: 17697543 [TBL] [Abstract][Full Text] [Related]
19. The phosphatidylinositol 3-kinases (PI3K) inhibitor GS-1101 synergistically potentiates histone deacetylase inhibitor-induced proliferation inhibition and apoptosis through the inactivation of PI3K and extracellular signal-regulated kinase pathways. Bodo J; Zhao X; Sharma A; Hill BT; Portell CA; Lannutti BJ; Almasan A; Hsi ED Br J Haematol; 2013 Oct; 163(1):72-80. PubMed ID: 23889282 [TBL] [Abstract][Full Text] [Related]
20. The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells. Li JP; Yang YX; Liu QL; Pan ST; He ZX; Zhang X; Yang T; Chen XW; Wang D; Qiu JX; Zhou SF Drug Des Devel Ther; 2015; 9():1627-52. PubMed ID: 25834401 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]